Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only

European Journal of Surgical Oncology

Volumn 35, Issue 4, 2009, Pages 352-355

  de Vries, R R ^a   Nieuwenhuijzen, J A ^a   Meinhardt, W ^a   Bais, E M ^a   Horenblas, S ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Bladder neoplasms; Combination therapy; Cystectomy; Lymph nodes; MVAC; Neoadjuvant therapy; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ABSCESS; ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CYSTECTOMY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMATOTHORAX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEUS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOCELE; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PELVIS LYMPH NODE; PRIORITY JOURNAL; SEPSIS; SURGICAL INFECTION; SURVIVAL RATE; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; URETER OBSTRUCTION; URINARY TRACT INFECTION;

ABDOMINAL NEOPLASMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; METHOTREXATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; REMISSION INDUCTION; SURVIVAL RATE; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 60849088238     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.07.001     Document Type: Article

References (9)

1. Wittekind Ch., Greene F.L., Henson D.E., Hutter R.V.P., and Sobin L.H. TNM classification of malignant tumours (2002), Wiley-Liss
2. Nieuwenhuijzen J.A., Bex A., Meinhardt W., et al. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol 174 1 (2005) 80-85
3. Therasse P., Eisenhauer E.A., and Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42 8 (2006) 1031-1039
4. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 3 (2001) 666-675
5. Herr H.W., Donat S.M., and Bajorin D.F. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 165 3 (2001) 811-814
6. Dodd P.M., McCaffrey J.A., Herr H., et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 17 8 (1999) 2546-2552
7. Sweeney P., Millikan R., Donat M., et al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?. J Urol 169 6 (2003) 2113-2117
8. der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 21 (2005) 4602-4608
9. Hall R.R., and Prout G.R. Staging of bladder cancer: is the tumor, node, metastasis system adequate?. Semin Oncol 17 5 (1990) 517-523